These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29661880)

  • 1. Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.
    Wassermann T; Reimer EK; McKinnon M; Stock W
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661880
    [No Abstract]   [Full Text] [Related]  

  • 2. Posaconazole-Induced Pseudohyperaldosteronism.
    Kuriakose K; Nesbitt WJ; Greene M; Harris B
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530850
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dangers of herbal teas: hypertension and weakness caused by liquorice-induced apparent mineralocorticoid excess.
    Pandher R; Puvanendran A; Diamond TH
    Med J Aust; 2020 Sep; 213(5):207-208.e1. PubMed ID: 32776334
    [No Abstract]   [Full Text] [Related]  

  • 5. A rare cause of hypertension in childhood: Answers.
    Kucuk N; Yavas Abalı Z; Abalı S; Canpolat N; Yesil G; Turan S; Bereket A; Guran T
    Pediatr Nephrol; 2020 Jan; 35(1):79-82. PubMed ID: 31541304
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cardiac arrest with syndrome of apparent mineralocorticoid excess].
    Meldgaard-Nielsen A; Laugesen E; Poulsen PL
    Ugeskr Laeger; 2014 Dec; 176(25A):. PubMed ID: 25497610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquorice-induced apparent mineralocorticoid excess presenting in the emergency department.
    Gallacher SD; Tsokolas G; Dimitropoulos I
    Clin Med (Lond); 2017 Feb; 17(1):43-45. PubMed ID: 28148579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent mineralcorticoid excess syndrome, an often forgotten or unrecognized cause of hypokalemia and hypertension: case report and appraisal of the pathophysiology.
    Bisogni V; Rossi GP; Calò LA
    Blood Press; 2014 Jun; 23(3):189-92. PubMed ID: 24053336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apparent mineralocorticoid excess manifested in an elderly patient with hypothyroidism.
    Inagaki K; Otsuka F; Otani H; Sato C; Miyoshi T; Ogura T; Makino H
    Am J Hypertens; 2007 Jan; 20(1):104-7; discussion 108. PubMed ID: 17198920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
    Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.
    Mahmood M; Abu Saleh O; Sohail MR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167540
    [No Abstract]   [Full Text] [Related]  

  • 12. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T; Al-Shaikh A
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole.
    Kidd D; Ranaghan EA; Morris TC
    Lancet; 1989 May; 1(8645):1017. PubMed ID: 2565490
    [No Abstract]   [Full Text] [Related]  

  • 14. Suspected posaconazole toxicity in a pediatric oncology patient.
    Martino J; Fisher BT; Bosse KR; Bagatell R
    Pediatr Blood Cancer; 2015 Sep; 62(9):1682. PubMed ID: 25950873
    [No Abstract]   [Full Text] [Related]  

  • 15. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
    González Rozas M; Alvarez Tundidor S; Pineda Alonso M
    Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
    Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
    J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.
    Hoffmann WJ; McHardy I; Thompson GR
    Mycoses; 2018 May; 61(5):337-339. PubMed ID: 29385285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
    Hummert SE; Green MR
    Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.